AngioDynamics (NASDAQ:ANGO) Price Target Raised to $15.00 at HC Wainwright

AngioDynamics (NASDAQ:ANGO) had its price target boosted by equities researchers at HC Wainwright from $14.00 to $15.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. HC Wainwright’s price target suggests a potential upside of 15.92% from the company’s previous close.

Separately, Canaccord Genuity Group lowered their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, October 4th.

AngioDynamics Stock Performance

NASDAQ ANGO opened at $12.94 on Friday. The firm has a market capitalization of $525.80 million, a P/E ratio of -2.12 and a beta of 0.59. The stock has a 50-day simple moving average of $8.12 and a two-hundred day simple moving average of $7.38. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $13.13.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The company had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. During the same period last year, the business earned ($0.05) earnings per share. AngioDynamics’s quarterly revenue was down .1% on a year-over-year basis. As a group, analysts forecast that AngioDynamics will post -0.41 earnings per share for the current year.

Institutional Investors Weigh In On AngioDynamics

A number of institutional investors have recently added to or reduced their stakes in ANGO. Segall Bryant & Hamill LLC lifted its holdings in AngioDynamics by 142.7% during the third quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier’s stock valued at $7,091,000 after purchasing an additional 535,958 shares in the last quarter. Millennium Management LLC raised its position in shares of AngioDynamics by 41.9% during the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock worth $10,850,000 after purchasing an additional 529,861 shares during the last quarter. Systematic Financial Management LP lifted its stake in AngioDynamics by 14.3% in the 3rd quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock valued at $18,752,000 after buying an additional 300,785 shares in the last quarter. First Eagle Investment Management LLC acquired a new stake in AngioDynamics in the 2nd quarter worth about $1,321,000. Finally, JPMorgan Chase & Co. increased its stake in AngioDynamics by 28.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock worth $4,304,000 after buying an additional 123,271 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.